Neumora Reshuffles Leadership Ahead Of NLRP3 IND And Phase 1 Readouts

Neumora Therapeutics has changed its leadership structure just before a set of development milestones that could define how investors and partners assess the company’s breadth beyond a single program. Joshua Pinto, Ph.D., has been appointed CEO after joining the company in 2021 as chief financial officer and later serving as president.

Neumora co-founder Paul Berns has been appointed executive chair of the board, and the company is also bringing in Doron Sagman, M.D., as chief medical officer. According to Fierce Biotech’s roundup, the appointments come ahead of Neumora’s goal of submitting an IND and initiating a phase 1 study of its NLRP3 inhibitor for patients with obesity, as well as data readouts from its phase 1 Alzheimer’s and schizophrenia programs.

Why The Timing Matters

This is more than a routine executive handoff. The company is making the change as it moves from portfolio building into a period where execution on clinical timelines becomes the main test. An obesity IND and first-in-human work on an NLRP3 inhibitor put Neumora into a market that is crowded, capital intensive and increasingly sensitive to differentiation. At the same time, phase 1 data in Alzheimer’s disease and schizophrenia mean management will need to explain results across very different therapeutic areas.

Putting Pinto in the CEO role suggests the board wants continuity from an executive who already sat close to capital allocation and corporate planning. Keeping Berns involved as executive chair preserves founder-level oversight while shifting day-to-day leadership to an internal operator. For a clinical-stage biotech with several upcoming catalysts, that structure can help reduce disruption during a transition that might otherwise raise questions about strategy.

The Leadership Changes

Sagman’s appointment adds a development executive with prior senior leadership roles at Eli Lilly Canada, including vice president of R&D/medical affairs, and a previous chief medical officer post at Mind Cure Health. That background is relevant because Neumora’s next phase is not centered on platform messaging alone. It is centered on trial execution, regulatory preparation and interpretation of early clinical signals.

The broader industry context in the same roundup also shows how companies are hiring around inflection points. Juvena Therapeutics named Julie Anne Smith as CEO as JUV-161 moves through phase 2a and as the company works through a global Eli Lilly collaboration tied to additional muscle and metabolic health programs using its AI-enabled JuvNET platform. Longevica Therapeutics named Prasun Mishra, M.D., as CEO after finalizing a $13 million in vivo mammalian screening program covering more than 1,000 small molecule candidates. Other companies in the roundup, including Entera Bio, HotSpot Therapeutics and Coultreon Biopharma, also made senior medical hires ahead of phase 3, clinic entry or phase 2 acceleration.

For Neumora, that puts its own changes in a familiar biotech pattern: boards tend to adjust leadership when the value of a company is about to depend less on narrative and more on whether management can convert a development plan into credible human data. In that sense, the signal is straightforward. Neumora is trying to align its leadership with an operating phase where clinical execution, not just asset ownership, will shape its next valuation step.